Cox Bryan F. 4

What Happened
Bryan F. Cox, Chief of Research at TriSalus Life Sciences (TLSI), sold a total of 3,184 shares across three transactions in March 2026 for combined proceeds of about $13,085. The sales were: 1,138 shares at $4.13 on 2026-03-11 ($4,700), 1,467 shares at $4.09 on 2026-03-12 ($6,000), and 579 shares at $4.12 on 2026-03-16 ($2,385). Per the filing footnote, these sales were made to satisfy tax withholding obligations associated with the vesting of previously granted restricted stock units (RSUs) and are not discretionary sales by the reporting person.

Key Details

• Transaction dates and prices:
  • 2026-03-11: 1,138 shares @ $4.13 = $4,700
  • 2026-03-12: 1,467 shares @ $4.09 = $6,000
  • 2026-03-16: 579 shares @ $4.12 = $2,385
• Total shares sold: 3,184; total proceeds ≈ $13,085.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: F1 — shares sold to satisfy tax withholding for vested RSUs; explicitly not a discretionary sale.
• Filing timeliness: Form 4 was filed on 2026-03-20. Because Form 4s are generally required within two business days of a reportable transaction, this filing appears to have been submitted several days after the transactions (4–9 days late) and may be marked late on EDGAR.

Context: These were tax-withholding sales tied to RSU vesting (a routine administrative action) rather than open-market, discretionary sell-offs. For retail investors, purchases tend to be more informative about insider sentiment; tax-withholding sales are common and do not necessarily indicate a view on the company's prospects.